Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...

Corcept Therapeutics Inc. (NASDAQ: CORT) is one of the 10 best biotech stocks with highest upside potential.

Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for ...

Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply ...

By Marleen Kaesebier BASEL, Switzerland, May 5 (Reuters) - Switzerland's biotech industry shifted toward private financing in 2025 as funding from capital markets remained difficult to obtain and ...

Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

While several major biotech companies are laying off employees by the hundreds, one is dropping billions in acquisitions.

Sellas Life Sciences CEO Angelos Stergiou met with European lawmakers to discuss the EU Biotech Act and drug approval processes, calling the talks 'exceptionally constructive.' The engagement comes as ...